FUNDING CANCER - Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (Multiple Mechanisms)
Sponsor: NIH
Multiple Mechanisms:
PAR-25-069, R01 Clinical Trial Optional
PAR-25-070, R21 Clinical Trial Not Allowed
Description: The NCI invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics impact cancer risk – specifically, GLP-1 or dual GLP-1/GIP-1 RAs. The focus on these agents is due to their reported effects on thyroid, prostate, and other cancer risks. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.
- Applications Due:
- February 5, 2025
- February 16, 2025
- June 5, 2025
- June 16, 2025
- October 5, 2025
- October 16, 2025
- February 5, 2026
- February 16, 2026
- June 5, 2026
- June 16, 2026
- October 5, 2026
- October 16, 2026
To view all current UVACCC funding opportunities, please click here.
For all open cancer-related funding opportunities, please click here.
There are no files to display.